Black Patients with RA Less Likely to Receive a Biologic, More Likely to Be Treated with Glucocorticoids Than Whites

A new study reveals that Black patients with rheumatoid arthritis were less likely to be prescribed a biologic treatment and more likely to use glucocorticoids, which carry a risk of serious long-term side effects. This study highlights ongoing racial disparities in the care of patients with rheumatic disease. Details of the study was shared at ACR Convergence, the American College of Rheumatology’s annual meeting.

Read more

AAOS Advances Biologics Initiative with Innovative Dashboard

The American Academy of Orthopaedic Surgeons (AAOS) continues to demonstrate its commitment to advancing the quality of musculoskeletal care in a fully transparent and scientific way. Debuting today as a new member benefit, the AAOS Biologics Dashboard is a dynamic online tool designed to help orthopaedic surgeons navigate the approval status of biologic-based interventions. The development of the AAOS Biologics Dashboard is just one of several efforts within the Academy’s Biologics Initiative that offers evidence-based guidance to the musculoskeletal health community. An additional effort is the revision of two biologics-related position statements, recently approved by the AAOS Board of Directors.

Read more

The Tri-Institutional Therapeutics Discovery Institute, Inc. Renews Partnerships with Takeda and Bridge Medicines, LLC

To date, work done within the Tri-I TDI has resulted in the launch of two New York City–based companies and the licensing of six therapeutic discovery programs.

Read more